Biotechnology · Bellevue, Washington, United States
$0.25
-10.71% (-$0.03)2026-08-24
Revenue$315.7K
Net Income-$1.0M
EPS$-0.10
Gross Margin27.4%
Market Cap$8.8M
Price Performance
Historical data including institutional events
Company Profile
K
Kuk Hwang
CEO & Executive Director
OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Switzerland, and South Korea.
The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma that is in phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1.
It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis.
In addition, the company distributes neurovascular intervention medical device and systems. OSR Holdings, Inc. is based in Bellevue, Washington.
